Fungal pleural infection due to Microascus gracilis with pulmonary aspergillosis after COVID-19 pneumonia

Zhi-Min Hu, Li-Na Mao, Ti-Ying Deng, Bin-Tao Su, Yi Yang, Bi-Lin Dong, Qing Xu, Shuo Yang
doi: https://doi.org/10.1101/2023.12.07.23298951

Abstract

Background Scopulariopsis/Microascus is a rare but devastating pathogen due to its intrinsic resistance to nearly all available antifungal agents. Microascus gracilis, an ascomycetous mould in the order Microascales, family Microascaceae, has recently emerged as a significant invasive pathogen causing opportunistic infections.

Objectives and Methods We present a case of pleural infection caused by M. gracilis with pulmonary aspergillosis in an immunocompromised man after COVID-19 pneumonia. To further understand the characteristics of the pathogen isolated from the patient, we identified the strain through mycological characteristics, matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MALDI-TOF MS) and internal transcribed spacer (ITS)-based sequencing, and performed in vitro drug susceptibility testing against common antifungal agents. Moreover, we assessed lymphocyte subsets and programmed cell death protein 1 (PD-1) expression in peripheral blood and pleural effusion to monitor the efficacy of therapy with thymosin-α-1 and intravenous immunoglobulin.

Results Filamentous fungi isolated from pleural fluid were identified as M. gracilis based on classical morphology, mass spectrometry and molecular biology methods. The susceptibility results in vitro revealed that multiple antifungal agents were inactive against the strain. Adjuvant immunomodulatory treatment successfully increased the levels of CD3+ T and CD4+ T cells while decreasing the levels of CD3+PD-1+ and CD4+PD-1+ T cells in both peripheral blood and pleural effusion.

Conclusions The immunocompromised host with opportunistic M. gracilis infection, rapid and accurate recognition through direct microscopic testing with calcofluor white and MOLDI-TOF MS, is the key to achieving a definite diagnosis, and a combination of antifungal therapy with immunomodulatory therapy is vital for improving survival.

1 INTRODUCTION

Pleural infection is a millennium-spanning condition that has been shown to be challenging to treat over many years.1 Fungi are uncommon causes of pleural infection and represent 3% of isolated pathogens,2 but there should be a strong suspicion of underlying dormant fungal infection for differential diagnosis when episodes of pleural effusions are encountered. Fungal infections tend to occur in patients with underlying immunocompromising conditions, and the most common isolated are Candida spp.3 As already well documented in medical articles, both immunocompromised and immunocompetent hosts are at an increased risk for developing fungal infections, most commonly Candida spp. and Aspergillus spp., but other opportunistic filamentous fungi have been emerging in recent years.4 In particular, even though infections of the genera Scopulariopsis/Microascus are very rare, as already reviewed, they are associated with high morbidity and mortality in the clinical setting due to delayed diagnosis and intrinsic resistance to currently available antifungal agents.4 These fungi are commonly isolated from soil, air, decaying organic material, dung, insects and moist indoor environments.4–10 M. gracilis, the species of the genus Microascus, was first isolated in 1962 from food in Japan by Inagaki.11 In the past, it was known as Scopulariopsis gracilis, which has been recategorized and designated M. gracilis.10 Due to the increase in predisposing factors in parallel with medical technological advances, the number of cases caused by these organisms has been on the rise.

2 CASE REPORT

An old male presented to the hospital with cough and yellow phlegm lasting for one week followed by fever and progressive dyspnoea that developed 2 days prior to admission. In December 2022, coronavirus disease 2019 (COVID-19) was diagnosed by RT‒PCR for severe acute respiratory syndrome coronavirus (SARS-CoV-2) and recovered with therapeutic strategies for COVID-19 pneumonia. Two month after discharge, the patient was diagnosed with nephrotic syndrome and received treatment with an immunosuppressive regimen of prednisone and cyclophosphamide. The patient reported a history of hypertension for almost 10 years, and his blood pressure was controlled well by using amlodipine and metoprolol. The patient’s underlying conditions included chronic obstructive pulmonary disease (COPD), interstitial pneumonia, and steroid-induced diabetes. On physical examination, he was revealed to be sick with wheezing and subcostal retraction requiring supplemental oxygen delivered by standard nasal cannula. There was no clinical evidence of onychomycosis or paronychia. At presentation, his body temperature was 37.6 °C, his blood pressure was 142/88 mmHg, and his pulse was 92 bpm. His blood work showed an elevated leukocyte count of 13.43×109 cells/L, haemoglobin 137 g/L, platelets 131×109/L, high sensitivity c-reactive protein (hsCRP) 11.1 mg/L, erythrocyte sedimentation rate (ESR) 19 mmHg, (1,3)-beta-d-glucan (G test) 100.65 pg/mL, and IL-6 11.94 pg/mL. Serologies for the galactomannan antigen test (GM test), syphilis, acquired immunodeficiency syndrome, and hepatitis A–E were negative. Blood and urine cultures were sterile. Chest computed tomography (CT) examination showed a new right-sided pneumothorax, and ground-glass opacities (GGOs) were diffusely distributed in both lungs, especially in the middle and lower lobes of the right lung (Figure 1A).

FIGURE 1
FIGURE 1

Chest computed tomography showed a new pneumothorax on the right lung, and ground-glass opacities were diffusely distributed in both lungs (A); a drainage tube, a cavity with an air-crescent sign and reduced hydropneumothorax in the right pleural cavity (B)

The timeline of diagnosis and targeted therapy is shown in Table 1. On Day 1, thoracentesis was performed, and the chest tube drainage system was maintained in an upright position below the patient’s chest to facilitate drainage. After that, the patient had recurrent infections in the lungs, and Acinetobacter baumannii and Aspergillus fumigatus were detected in sputum. Pulmonary symptoms were usually reduced or alleviated by empirical broad-spectrum antibiotics, including ceftriaxone/tazobactam, levofloxacin, fluconazole (FLZ) and voriconazole (VRC), for approximately 3 weeks. On Day 32, Enterococcus faecalis was incubated in the pleural fluid, and anti-biotherapy was adjusted to vancomycin for 3 weeks. The signs and symptoms of spontaneous hydropneumothorax were improved. On Day 65, the pathogen causing pleural reinfection was Streptococcus sanguinis, and the therapeutic agent was switched to ceftriaxone/tazobactam for 2 weeks. On Day 73, the symptoms of pneumonia and empyema were alleviated, and he was discharged home with intercostal drainage (ICD) in situ. Eight days later, he was readmitted because of worsening of dyspnoea, cough and wheezing, and no fever. According to the patient’s recollection, the chest drain was unsecure for fixation and accidental removal in house. His blood work showed a low absolute lymphocyte count 320/L. Abnormal laboratory findings included elevated hsCRP 189.3 mg/L and peripheral blood cytomegalovirus 1070 copies/ml. Repeated CT revealed a drainage tube, a cavity with an air-crescent sign and reduced hydropneumothorax in the right pleural cavity (Figure 1B). Klebsiella pneumoniae was detected in sputum, and anti-biotherapy was switched to latamoxef and valganciclovir for two weeks. After unplanned extubation, the new pleural catheter was reintubated away from the original region (Figures 2A). The culture from the removed chest tube was positive for mould growth. From Day 89 to Day 93, multiple cultures of pleural fluid from the new tube were positive for the same mould. Calcofluor white staining revealed many pigmented, septate fungal hyphae (Figures 2B) of the pleural fluid and septate fungal hyphae of BALF. In addition, the sample was separately inoculated onto Sabouraud’s dextrose agar (SDA) at 35 °C. The T-spot test and MTB/RIF GeneXpert detection assays were negative. Both G and GM tests were negative in serum and pleural fluid. However, the antifungal strategy of caspofungin (CAS, 50 mg/day) and posaconazole (POS, 0.3 g/day) was initiated despite the discouraging result of in vitro susceptibilities, and improvement of pleural effusion was achieved after 5 weeks of treatment. No adverse events were reported. On Day 95, intermittent fever was observed after the administration of the combined antifungal therapy. The serum and pleural fluid GM tests were still negative, and blood cultures were all sterile. A quantitative real-time PCR assay was developed to measure the human cytomegalovirus (HCMV) DNA load in peripheral blood, which was 2589 copies/ml. The BALF collected for metagenomics next generation sequencing (mNGS) showed high sequence numbers and relative abundance of Pneumocystis jirovecii, Aspergillus fumigatus, HCMV and EBV. The BALF GM antigen test was positive. With regard to the patient’s immunological and infectious condition, clindamycin 1.2 g/day, thymosin-α-1 4.8 mg/week and intravenous immunoglobulin 400 mg/kg/week were added. On Day 119, the symptoms of the lungs and pleural infection were relieved, the chest tube was removed, and the culture of the pleural catheter, pleural effusion and sputum were all negative. On Day 146, the nucleic acid of cytomegalovirus was normal, and the high level of CRP and persistent low level of absolute lymphocyte count were relieved. A chest CT scan showed that bilateral lung infection and pneumothorax were partly absorbed, lung tissue compression was less than 3%, and pleural effusion was reduced. The patient was discharged with no chief complaints and switched to terbinafine (TEB) 250 mg/day combined with POS 0.3 g/day for 4 weeks. After 3 months of follow-up, the patient had no obvious discomfort.

FIGURE 2
FIGURE 2

The image showed the new intercostal catheter on the right-sided chest(A). Calcofluor white staining showed the pigmented, septate fungal hyphae of pleural effusion, ×400 (B). The picture displays Microascus gracilis on Sabouraud’s dextrose agar after 5 days of incubation at 35 °C (C). Microscopic examination showing hyaline septate hyphae with bottle-shaped conidiogenous cells along with obovate-shaped, smooth conidia arranged in short chains, lactophenol cotton-blue staining, ×400 (D). The characteristic spectrometry of M. gracilis identified by MOLDI-TOF MS (E).

View this table:
TABLE 1 Timeline of events

3 MATERIALS AND METHODS

The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page, have been adhered to and that appropriate ethical review committee approval has been received.

3.1 Fungal pathogen identification

Microbiological tests were implemented with pleural fluid, puncture drainage tubes and bronchoalveolar lavage fluid (BALF). The isolates obtained were identified by examination of micromorphological and macromorphological characteristics. After pretreatment with 70% formic acid and α-cyano-4-hydroxycinnamic acid (HCCA, Sigma‒Aldrich). The strains were identified by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MALDI-TOF MS, Zybio EXQ2000, Zhongyuan Huiji Biotechnology Co. Ltd.) according to the standard operation protocol.12 Mycelia were mechanically disrupted by liquid nitrogen grinding, followed by genomic DNA extraction using QIAGEN’s DNeasy® Plant Kit.13 The internal transcribed spacer region (ITS) was amplified with the primer pair ITS1 (5’-TCCGTAGGTGAACCTGCGG-3’) and ITS4 (5’-TCCTCCGCTTATTGATATGC-3’). DNA sequences were analysed using NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi).

3.2 Antifungal susceptibility testing

In vitro susceptibility was tested according to the guidelines presented in document M38-A2 of the Clinical and Laboratory Standards Institute (CLSI).14 The minimum inhibitory concentration (MIC) was determined visually as the concentration that resulted in 100% inhibition. The minimal effective concentration (MEC) endpoint was taken as the lowest concentration at which the visual growth pattern change from granular to filamentous growth was detected, microscopically seen as restricted hyphal growth.14,15

3.3 Flow cytometry analysis

To monitor lymphocyte subsets and programmed cell death protein 1 (PD-1) expression in peripheral blood and pleural effusion to evaluate the efficacy of therapy with thymosin-α-1 and intravenous immunoglobulin, simultaneous identification and enumeration of T lymphocytes in whole blood and multicolour flow cytometric analysis of lymphocyte subsets as well as CD4+ and CD8+ T-cell subset ratios were determined using an automated AQUIOS cytometer (Beckman Coulter), as per the manufacturer’s instructions for use. Each site had an instrument and all needed reagents. Ten millilitres of pleural fluid was passed through a 40 µm filter, and the cellular pellet was spun down. Then, red blood cells (RBCs) were lysed using a soft RBC lysing solution (Beckman Coulter). Cellular viability was then assessed using fluorescent reactive dye.16

3.4 Literature review

We performed a literature search of Scopulariopsis or Microascus pleural infection and Scopulariopsis gracilis or Microascus gracilis infection published from 1962 to 2023 via the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). In addition, the references cited in these reports have been reviewed to identify additional cases that were not found in the PubMed database. The review included an assessment of all demographic features, including year/nation, age/gender, underlying disease, transplant type, systemic antifungal agents before infection, involved sites, identified fungal organisms, treatment and therapeutic outcomes. Only those cases that met the criteria for “proven invasive fungal disease” caused by moulds as described by the consensus group of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) were included in this evaluation.17

4 RESULTS

4.1 M. gracilis and A. fumigatus were identified according to classical morphology, mass spectrometry and molecular biology methods

Colonies grown on SDA were first visible on Day 2 of incubation and developed into small mould colonies over the next few days (Figure 2C). The colonies were initially pale but developed a velvety and olivaceous grey colour after 2 weeks. Lacto-phenol cotton blue mounts of the colonies showed conidiophores mostly irregularly branched, usually consisting of clusters of 2 to 3 annellides borne on short branches. Annellides lageniform or somewhat cylindrical with a slightly swollen base. Conidia subspherical to ellipsoidal, with truncate base and rounded or pointed aped, arranged in long chains (Figure 2D). M. gracilis and A. fumigatus were identified by mycological characteristics, MALDI-TOF MS (Figure 2E) and ITS-based sequencing (accession no. OR131328).

4.2 M. gracilis manifests as a multidrug-resistant strain

The results revealed that multiple antifungal agents were inactive against M. gracilis, with MIC values of 4 μg/ml for amphotericin B (AMB), 8 μg/ml for VRC, > 8 μg/ml for POS, >16 μg/ml for itraconazole (ITC), >64 μg/ml for 5-flucytosine (5-FC), >256 μg/ml for FLZ, and minimal effective concentration (MEC) values all > 8 μg/ml for echinocandins. The susceptibility profiles of A. fumigatus showed POS 0.06 μg/ml, ITC 0.12 μg/ml, VRC 1 μg/ml, AmB 4 μg/ml, 5-FC >64 μg/ml and echinocandins all 8 μg/ml.

4.3 Adjuvant immunomodulatory treatment successfully increased the levels of CD3+ T and CD4+ T cells while decreasing the levels of CD3+PD-1+ T and CD4+PD-1+ T cells

The inflammatory indicators, lymphocyte subsets and PD-1 expression in peripheral blood and pleural effusion were evaluated before and after adjuvant immunomodulatory treatment with thymosin-α-1 and intravenous immunoglobulin. The levels of CD3+ T cells and CD4+ T cells were alleviated (Figure 3), while CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly both in blood (Figure 4) and pleural effusion (Figure 5) after the immunomodulatory agents were administered. Other abnormal biochemical biomarkers, such as hsCRP and IL-6 in peripheral blood and LDH, ADA, IL-1β and IL-6 in pleural diffusion, all declined substantially. (Table 2)

FIGURE 3
FIGURE 3

Flow cytometry results displayed the level of CD3+ T cells and CD4+ T cells were alleviated in peripheral blood after the immunomodulatory agents administered.

FIGURE 4
FIGURE 4

Flow cytometry results reveals the level of CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly in peripheral blood after the immunomodulatory agents administered.

FIGURE 5
FIGURE 5

Flow cytometry results reveals the level of CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly in pleural effusion after the immunomodulatory agents administered.

View this table:
TABLE 2 Comparison of abnormal biochemical and immunological indicators before and after the administration ofimmunomodulatory regimens

4.4 Literature review

A review of the English literature since 1962 identified 5 cases reported as proven pleural Scopulariopsis/Microascus infections.18–22 The reported cases listed in Table 3 had a median age of 52.8 years (range 27-70 years) and represented 6 males. Of these cases, 2 were from the USA, and 1 each was from Belgium, India, France and China. Of these patients, 80% had solid organ transplant (SOT), and all were associated with lung transplantation. Sixty percent of patients were treated with azole antifungal prophylaxis. Because of the isolate morphologically identified as M.cinereus was found after sequencing to be from M. gracilis.4,10 The most commonly identified species was M. gracilis (3/6, 50%), followed by S. brumptii (2/6, 33.3%) and S. acremonium (1/6, 16.7%). Combined therapies were performed when diagnostic clues were found, but the therapeutic outcomes were worse, as 83.3% of patients died.

View this table:
TABLE 3 Demographic features of reported cases with indicated pleural infection by Scopulariopsis!Microascus species

To date, only six proven cases of M. gracilis infections have been reported, including two cases of disseminated infection,20,22 two cases of invasive bronchopulmonary infection,23,24 and each case of primary subcutaneous infection25 and keratitis.26 A total of 83.3% of cases were underlying diseases that compromised the immune system locally or systemically. A total of 66.7% of patients also received azole antifungal prophylaxis. In addition, 66.7% were cured successfully, while the salvage treatment for two disseminated patients failed.

5 DISCUSSION

M. gracilis, the teleomorph of Scopulariopsis/Microascus spp., is a rare opportunistic fungus associated with human disease and is commonly found in soil, decaying organic matter and in-house environments.4,7,8,10,22–26 There is a paucity of information available concerning clinical infections caused by M. gracilis. Among the ninety-seven clinical strains morphologically identified as Scopulariopsis/Microascus spp., M. gracilis was the second most commonly isolated species and was most frequently isolated from BALF and sputum samples.8 Most of them, according to the clinical features, were determined to have fungal colonization.8 The diagnosis of Scopulariopsis/Microascus infections is challenging because of the delay in microbiological study completion.4 Precise and timely identification of these pathogens to species can be extremely important when recovered from high-risk patients. However, morphological conclusion requires sporulating culture, which considerably delays the diagnosis, while the developed DNA-based assays for identification are rapid and reliable.27 Typically, the isolate morphologically identified as M.cinereus was found after sequencing to be from M. gracilis.20 Our strain accurately identified by morphological features, mass spectrometry and ITS-based sequencing is the seventh invasive M. gracilis infection, as well as the sixth pleural infection caused by Scopulariopsis/Microascus spp.. Notably, in comparison to DNA-based assays, mass spectrometry analysis based on the updated database offers a cost/time-saving and accurate clinical working protocol for identifying both the genus and species levels of the Scopulariopsis/Microascus genera.

The development of spontaneous hydropneumothorax is a complication of post-COVID-19 pneumonia due to rupture of the small airway.28 A history of recent COVID-19 infection is a risk factor for pleuropulmonary infections, particularly in patients with comorbidities, structural defects such as bronchopleural fistula, and immunosuppressive therapies.29 The presence of M. gracilis may represent colonization or may cause localized infections at the usual residential location of the superficial tissue or the lungs.22,30 As the most representative aetiologic agent in Scopulariopsis/Microascus spp. infection of the pleura in extremely limitated data, M. gracilis occurs less frequently but causes refractory and fatal disseminated infections. Opportunistic infections of this extremely rare fungus have been reported mostly in immunocompromised patients, with most severe infections occurring in solid organ transplant patients, particularly lung transplant patients.18,20–24 We suspected that treatment with corticosteroids for nephrotic syndrome might have transiently suppressed immunity, resulting in opportunistic infection. Prognosis is poor, and mortality is high in immunosuppressed patients.8,31 Furthermore, it is worth mentioning that more than 60% of patients acquired the infection when they were under antifungal prophylaxis with azole agents. The selective pressure of antifungal prophylaxis may also contribute to the appearance of rarely invasive fungal infections, caused by moulds that are often intrinsically resistant to some classes of antifungals, which have been described as opportunistic pathogens in patients with a variety of underlying diseases.32–34 Pneumocystis pneumonia most often occurs in immunocompromised hosts, with intensified or prolonged immunosuppression, notably with corticosteroids and subsequent cytomegalovirus (CMV) infections.35 Coinfection with CMV may contribute to further immune dysregulation in haematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients.36 A total of 42.9% of SOT patients had a proven CMV infection that occurred in concurrent infection with Scopulariopsis/Microascus spp.,18,23,37,38 possibly because CMV can affect several components of the defence system and, therefore, could enhance the pathogenicity of other infectious agents.18,23,39 It is worth noting that our patient experienced a persistent low absolute lymphocyte count. Based on the analysis of lymphocyte subsets in peripheral blood and pleural effusion through flow cytometry assays, the number of T lymphocytes was significantly decreased, and T-cell exhaustion occurred. The host cannot control infections effectively because of T-cell exhaustion.40 PD-1 together with programmed death-ligand 1 (PD-L1) is a key biomarker of lymphocyte depletion,41 and upregulation of PD-1 in exhausted T cells as an immunosuppressive receptor was observed during the progression of symptomatic stages of infections, which contributes to the evolution of the severe form of the symptoms. Prognosis largely depends on the immune status of the patient, and immune reconstitution is considered essential when combating invasive fungal infections.8 In conclusion, elevated PD-1 levels in CD4+ T cells were associated with the inhibition of cell proliferation and decreased effector functions;42 in contrast, blocking or downregulating PD-1 reversed exhausted T cells, and immunosuppressive status resulted in recovery and enhancement of host innate immunity.

The potential origin of infection is vastly diverse. Outbreaks of fungal keratitis and invasive disease due to contaminated grafts used to store the issued corneoscleral button,26 soil contamination43,44 or inhaled pollution,45, respectively, have been described in immunocompetent hosts. In addition to the severe immunocompromised host susceptible to invasion of the opportunistic Scopulariopsis/Microascus, especially in those patients who had undergone solid organ transplants, transmission of the fungus from the donor was possible,4,21 and the fungus might have been accessed into the pleural space during prehospital placement of thoracostomy tubes21 or introduced into the skin and then into the vessels through trauma at a catheter site.46 Our patient was another case of catheter-related pleural infection contaminated by the indoor environment. To minimize the fungal equivalent and avoid persistent infection, the contaminated catheter should be removed immediately. The delayed diagnosis and the high rates of resistance of Scopulariopsis/Microascus to practically all current antifungals 8,31,47,48 are responsible for the high mortality associated with disseminated infections.18,20,21,22 A spread of pulmonary Scopulariopsis/Microascus to the pleura is unlikely in the present case because only pleuritis was detected without apparent pulmonary Scopulariopsis/Microascus.

Currently, fungal empyema therapy is not protocolized, and combinations that include available agents can be used due to the variable penetration of systemically administered antifungals into the pleural cavity.49 First-line treatment for systemic fungal infections, AMB and VRC, and other antifungal agents are ineffective against Scopulariopsis/Microascus spp. in vitro. The lack of correlation between in vitro and in vivo studies and the intrinsic resistance of fungal pathogens to many of the available antifungals limits successful therapeutic options.50 Susceptibility testing using CLSI or EUCAST methodologies usually shows high MIC values for all currently approved antifungal agents.8,47 No cut-off values have been determined, as there are insufficient data to correlate MIC values and clinical outcomes.51 Nevertheless, in vitro synergy has been demonstrated with combinations of POS and TEB, POS and caspofungin (CAS), AMB and CAS, and three drugs in combination.30,52 L-AMB (3–10 mg/kg/day) and VRC,52,53 VRC alone (i.v. and then oral step-down therapy), and lipid formulations of AMB with other antifungal agents can be moderately recommended.52 VRC with an echinocandin and TEB is marginally recommended.20,52 Limited literature on M. gracilis indicates higher MICs in vitro, 20,22,23,25,30,48 approximately 85.7% of the isolates had high concentrations for AmB, CAS, VOR and POS, except one case had relatively low concentrations for AMB,22 CAS,48 VOR and POS,23 respectively. All strains had high MIC values for FLZ, ITC, and 5-FC. The MEC values of micafungin were 0.2523 and 1 μg/ml,22 and the MIC of isavuconazole was established at 2 μg/ml.22,54 It is worth mentioning that the value of TEB fluctuated obviously from 1 to 16 μg/ml. The fractional inhibitory concentration indices (FICIs) range of CAS, POS, and TRB combination against M. gracilis was from 0.321 to 0.320, which appear to be promising, with a synergistic effect on M. gracilis.30 The MIC, POS, and TRB combination in invasive infections warranted to be an effective therapy in clinical practice.23,24 The other therapeutic strategies include nebulized micafungin for the treatment of Scopulariopsis/Microascus tracheobronchitis,55 combination of treatment for Scopulariopsis/Microascus pneumonia, which included surgery, triple combination of antifungal drugs, and granulocyte-colony stimulating factor.56 Moreover, an investigational antifungal within the orotomide class that is currently in late-stage clinical development, olorofim (formerly F901318), demonstrated good in vitro activity against the majority of Scopulariopsis/Microascus isolates tested, with an MIC90 value of 0.125 mg/L and a modal MIC of 0.03 mg/L.57 Surgical debridement (where feasible) and reversal of the host’s innate immunodeficiency are critical to survival and are strongly recommended.52 Particularly, for immunocompromised patients, intravenous immunoglobulin was essential to reverse the immunological crisis and was obtained with highly effective clinical outcomes.23 Although there is limited information about thymosin α1 (Tα1) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, the favourable combination of Tα1 with an anti-PD-1 antibody has already been postulated experimentally. Tα1 may be a treatment option for invasive fungal infection in immunocompromised hosts, but efficacy and safety data remain limited. Our immunocompetent patient was initially treated with CAS combined with POS; when the symptoms and critical biological index were relieved, the POS and TRB combination started as a sequential therapy until he was cured. Moreover, a combination of antifungal therapy with immunomodulatory therapy was shown to be an effective intervention.

In summary, the patient’s underlying comorbidities, history of recent COVID-19 infection, immunosuppressive therapy, antifungal prophylaxis with azole drugs, cytomegaloviremia, lymphocyte depletion and indwelling catheter may have played a role in the pleural seeding of M. gracilis. Fortunately, our patient was beneficial for successful management in a multimodal manner, including reversal or revocation of underlying predisposing factors, early administration of suitable antifungal agents, and adjuvant immunomodulatory treatment in which his condition did not progress into disseminated Scopulariopsis/Microascus. Although infection with M. gracilis is uncommon and rarely pathogenic in the pleural cavity, clinicians and microbiologists should be aware of the potential of M. gracilis infection in immunocompromised individuals at risk of opportunistic infections. Early and definitive diagnosis thorough direct microscopic testing with calcofluor white, as well as MOLDI-TOF MS, which has been suggested as a valuable tool for identification at the genus and the species level, is the key to rapidly recognize this rare pathogenic fungus. Achieving an accurate diagnosis along with appropriate antifungal management is vital for improving survival.

AUTHOR CONTRIBUTIONS

Zhi-Min Hu: Investigation; methodology; formal analysis; writing–review and editing; writing – original draft; resources; visualization; data curation. Li-Na Mao: collected and interpreted the clinical data and wrote the manuscript. Ti-Ying Deng: Investigation; formal analysis; resources. Bin-Tao Su: revised the manuscript critically for important content. Yi Yang: carried out the radiological examination. Bi-Lin Dong: carried out the microbiological examination and nucleotide sequencing. Qing Xu: Investigation; formal analysis. Shuo Yang: Methodology; supervision; project administration; writing – review and editing. All the authors have read and approved the final manuscript.

Data Availability

All data produced in the present work are contained in the manuscript.

CONFLICT OF INTEREST STATEMENT

No potential conflict of interest was reported by the authors.

ACKNOWLEDGEMENTS

This work was supported by the Wuhan Health Scientifc Research Key Project (No.WX18A06), and the Wuhan Health Scientifc Research Program(No.WH21C21).

REFERENCES

  1. 1.↵
    Sundaralingam A, Banka R, Rahman NM. Management of pleural infection. Pulm Ther. 2021;7(1):59–74.
    OpenUrl
  2. 2.↵
    Hassan M, Cargill T, Harriss E, et al. The microbiology of pleural infection in adults: a systematic review. Eur Respir J. 2019;54(3):1900542.
    OpenUrl
  3. 3.↵
    Hassan M, Patel S, Sadaka AS, et al. Recent insights into the management of pleural infection. Int J Gen Med. 2021;14:3415–3429.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Pérez-Cantero A, Guarro J. Current knowledge on the etiology and epidemiology of Scopulariopsis infections. Med Mycol. 2020;58(2):145–155.
    OpenUrl
  5. 5.
    Barron GL, Cain RF, Gilman JC. The genus Microascus. Can.J.Botany. 1961;39:1609–1631.
    OpenUrl
  6. 6.
    Samson RA, Houbraken J, Thrane U, Frisvad JC, Andersen B. Food and Indoor Fungi. Westerdijk Laboratory Manual series: 2, second edition. 2 ed. Utre cht: Westerdijk Fungal Biodiversity Institute. 2019;481 p. (Westerdijk Laboratory Manual series).
  7. 7.↵
    Woudenberg JHC, Meijer M, Houbraken J, Samson RA. Scopulariopsis and scopulariopsis-like species from indoor environments. Stud Mycol. 2017;88:1–35.
    OpenUrl
  8. 8.↵
    Sandoval-Denis M, Sutton DA, Fothergill AW, et al. Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in v itro responses to antifungal drugs. J Clin Microbiol. 2013;51(12):3937–3943.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Iwen PC, Schutte SD, Florescu DF, Noel-Hurst RK, Sigler L. Invasive Scopulariopsis brevicaulis infection in an immunocompromised patient and review o f prior cases caused by Scopulariopsis and Microascus species. Med Mycol. 2012;50(6):561–569.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Sandoval-Denis M, Gené J, Sutton DA, et al. Redefining microascus, Scopulariopsis and allied genera. Persoonia. 2016;36:1–36,
    OpenUrlCrossRef
  11. 11.↵
    Inagaki N. On some fungi isolated from foods (I). Trans Mycol Soc Japan.1962;4(1):1–5.
    OpenUrl
  12. 12.↵
    Wei L, Shao J, Song Y, et al. Performance of matrix-assisted laser desorption Ionization-time of flight mass spectrometry for identification of Scedosporium, Acremonium-like, Scopulariopsis, and Microascus specie. Front Microbiol. 2022;13:841286.
  13. 13.↵
    Bellemare A, John T, Marqueteau S. Fungal genomic DNA extraction methods for rapid genotyping and genome sequencing. Methods Mol Biol. 2018;1775: 11–20.
    OpenUrl
  14. 14.↵
    Rex JH, Alexander BD, Andes D, et al. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved Standard. 2 nd ed. M38-A2 National Committee for Clinical Laboratory Standards; 2008.
  15. 15.↵
    Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. 2nd ed. CLSI supplement M6 Wayne,PA:Clinical and Laboratory Standards Institute; 2020.
  16. 16.↵
    Juan C. Nieto, Carlos Zamora, José M. Porcel, et al. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung ade nocarcinoma patients. Sci Rep. 2019;9:2996.
    OpenUrl
  17. 17.↵
    De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of C ancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Con sensus Group. Clin Infect Dis. 2008;46:1813–1821.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Wuyts WA, Molzahn H, Maertens J et al. Fatal Scopulariopsis infection in a lung transplant recipient: a case report. J Heart Lung Transplant. 2005;24:230 1–2304.
    OpenUrlCrossRef
  19. 19.
    Shankar EM, Vignesh R, Barton RC, et al. Hydrothorax in association with Scopulariopsis brumptii in an AIDS patient in Chennai, India. Trans R Soc Tr op Med Hyg. 2007;101(12):1270–1272. doi:10.1016/j.trstmh.2007.09.008.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Miossec C, Morio F, Lepoivre T et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol. 2011;49:2743–2747.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Shaver CM, Castilho JL, Cohen DN, et al. Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurement. Am J Transplant. 2014;14:2893–2897.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Ding Y, Steed LL, Batalis N. First reported case of disseminated Microascus gracilis infection in a lung transplant patient. IDCases. 2020; 22:e00984.
    OpenUrl
  23. 23.↵
    Huang L, Chen W, Guo L, et al. Scopulariopsis/Microascus isolation in lung transplant recipients: a report of three cases and a review of the literature. M ycoses. 2019;62(10):883–892.
    OpenUrl
  24. 24.↵
    Gao B, Guo L, Zhao L, et al. Case Report of a Successfully Treated Scopulariopsis Infection in a Bilateral Lung Transplant Recipient. Exp Clin Transpla nt. 2023;21(3):275–278.
    OpenUrl
  25. 25.↵
    Mhmoud NA, Siddig EE, Nyuykonge B, Bakhiet SM, van de Sande WWJ, Fahal AH. Mycetoma caused by Microascus gracilis: a novel agent of human eumycetoma in Sudan. Trans R Soc Trop Med Hyg. 2021;115:426–430.
    OpenUrl
  26. 26.↵
    Wilde C, Messina M, Moshiri T, Snape SE, Maharajan S. Interface Scopulariopsis gracilis fungal keratitis following Descemet’s stripping automated endoth elial keratoplasty (DSAEK) with a contaminated graft. Int Ophthalmol. 2018;38(5):2211–2217.
    OpenUrlPubMed
  27. 27.↵
    Kordalewska M, Jagielski T, Brillowska-Dąbrowska A. Rapid assays for specific detection of fungi of Scopulariopsis and Microascus genera and Scopulario psis brevicaulis species. Mycopathologia. 2016;181(7-8):465–74.
    OpenUrl
  28. 28.↵
    Kumar R, Mishra N. Lung decortication for spontaneous hydropneumothorax in post COVID patients: A case series. Perioper Care Oper Room Manag. 2022;29:100279.
    OpenUrl
  29. 29.↵
    Patel VM, Patel SV, Singletary K, Pacheco L. Recurrent hydropneumothorax after COVID-19. Cureus. 2023;15(3):e36208.
    OpenUrl
  30. 30.↵
    Yao L, Wan Z, Li R, Yu J. In vitro triple combination of antifungal drugs against clinical Scopulariopsis and Microascus species. Antimicrob Agents Chem other. 2015;59:5040–5043.
    OpenUrl
  31. 31.↵
    Paredes K, Capilla J, Mayayo E, Guarro J. Virulence and resistance to antifungal therapies of Scopulariopsis species. Antimicrob Agents Chemother. 2016;6 0(4):2063-2068.
    OpenUrl
  32. 32.↵
    Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Di s. 2017;64:1619–1621.
    OpenUrl
  33. 33.
    Jenks J, Reed SL, Seidel D, et al. Rare mold infections caused by Mucorales, Lomentospora prolificans and Fusarium, San Diego: the role of antifungal c ombination therapy. Int J Antimicrob Agents. 2018;52:706-712.
  34. 34.↵
    Stemler J, Salmanton-García J, Seidel D, et al. Risk factors and mortality in invasive Rasamsonia spp. infection: analysis of cases in the FungiScope(R) registry and from the literature. Mycoses. 2020;63:265–274.
    OpenUrlCrossRef
  35. 35.↵
    Apostolopoulou A, Fishman JA. The pathogenesis and diagnosis of Pneumocystis jiroveci pneumonia. J Fungi (Basel). 2022;8(11):1167.doi:10.3390/jof811116 7.
    OpenUrlCrossRef
  36. 36.↵
    Gea-Banacloche, J.,Komanduri, K., Carpenter, P., et al. National institutes of health hematopoietic cell transplantation late effects initiative: the immune dysr egulation and pathobiology working group report. Biol Blood Marrow Transplant. 2017;23(6),870–881.
    OpenUrlPubMed
  37. 37.↵
    Swick BL, Reddy SC, Friedrichs A, Stone MS. Disseminated Scopulariopsis–culture is required to distinguish from other disseminated mould infections. J Cutan Pathol. 2010;37(6):687–691.
    OpenUrlCrossRefPubMed
  38. 38.↵
    Helander L, Stark M. Fatal Scopulariopsis brumptii in a pediatric immunocompromised host. Fetal Pediatr Pathol. 2017;36(1):82–86.doi:10.1080/15513815.2016.1267283.
    OpenUrlCrossRef
  39. 39.↵
    Singh N. Interactions between viruses in transplant recipients. Clin Infect Dis. 2005;40(3):430–436.
    OpenUrlCrossRefPubMed
  40. 40.↵
    E. J. Wherry. T cell exhaustion. Nature Immunology. 2011;12(12):492–499.
    OpenUrlCrossRefPubMed
  41. 41.↵
    Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–2194.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Sellami A, Boudaya S, Makni F, et al. Disseminated infection by Scopulariopsis brevicaulis. J Mycol Med. 2003;13:203–206.
    OpenUrl
  44. 44.↵
    Chen-Scarabelli C, Scarabelli TM. Fungal Endocarditis due to Scopulariopsis. Ann Intern Med. 2003;139(9):W77.doi:10.7326/0003-4819-139-9-200311040-00022-w1.
    OpenUrlCrossRef
  45. 45.↵
    Celard M, Dannaoui E, Piens MA, et al. Early Microascus cinereus endocarditis of a prosthetic valve implanted after Staphylococcus aureus endcarditis of the native valve. Clin Infect Dis. 1999;29:691–692.
    OpenUrlPubMedWeb of Science
  46. 46.↵
    Steinbach WJ, Schell WA, Miller JL, Perfect JR, Martin PL. Scopulariopsis brevicaulis infection in a perdiatric stem-cell transplant patient treated with vor iconazole and caspofungin and a review of Scopulariopsis infections in immunocmpromised patients. J Infect. 2004;48:112–116.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    Aguilar C, Pujol I, Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother. 1999;43:1520–1522.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    Skóra M, Bulanda M, Jagielski T. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species. Antimicrob Agents Chemother. 2015;59:5827–5829.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    Matsuda T, Koreeda Y, Mataki H, et al. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: exc ellent penetration of voriconazole and micafungin into pleural fluid. Intern Med. 2010;49(12):1163–1169
    OpenUrlCrossRefPubMed
  50. 50.↵
    Salmanton-García J, Koehler P, Kindo A, et al. Needles in a haystack: extremely rare invasive fungal infections reported in FungiScope®-global registry fo r emerging fungal infections. J Infect. 2020;81:802–815.
    OpenUrlCrossRef
  51. 51.↵
    Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, et al. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scop ulariopsis brevicaulis. Antimicrob Agents Chemother 2006;50:2248–2250.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    Bupha-Intr O, Butters C, Reynolds G, et al. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021. Intern Med J. 2021;51(Suppl 7):177-219.
  53. 53.↵
    Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, et al. Invasive Scopulariopsis alboflavescens infection in patient with acute myeloi d leukemia. Int J Hematol 2018;108:658–664.
    OpenUrl
  54. 54.↵
    Arroyo MA, Walls TB, Relich RF, Davis TE, Schmitt BH. The brief case: Scopulariopsis endocarditis-a case of mistaken Takayasu’s arteritis. J Clin Micro biol. 2017;55:2567–2572.
    OpenUrl
  55. 55.↵
    Los-Arcos I, Berastegui C, Martín-Gómez MT, et al. Nebulized micafungin treatment for Scopulariopsis/Microascus tracheobronchitis in lung transplant reci pients. Antimicrob Agents Chemother. 2021;65(6):e02174–20.
    OpenUrl
  56. 56.↵
    Ustun C, Huls G, Stewart M, Marr KA. Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor. Mycopathologia. 2006,162(4):299-302.
  57. 57.↵
    Wiederhold NP, Patterson HP, Sanders CJ, Cañete-Gibas C. Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/ Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species. Mycoses. 2023;66(3):242–248.
    OpenUrl
Back to top
Posted December 08, 2023.
Download PDF
Data/Code
Email
Fungal pleural infection due to Microascus gracilis with pulmonary aspergillosis after COVID-19 pneumonia
Zhi-Min Hu, Li-Na Mao, Ti-Ying Deng, Bin-Tao Su, Yi Yang, Bi-Lin Dong, Qing Xu, Shuo Yang
medRxiv 2023.12.07.23298951; doi: https://doi.org/10.1101/2023.12.07.23298951
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area